版本:
中国

BRIEF-Invivo Therapeutics qtrly adjusted net loss per diluted share 0.21

March 10 Invivo Therapeutics Holdings Corp :

* Invivo Therapeutics reports 2016 year-end financial results and business update

* Invivo Therapeutics Holdings Corp qtrly GAAP net loss per diluted share $0.17

* Qtrly adjusted net loss per diluted share 0.21

* Invivo Therapeutics holdings- "ended year with about $33 million in cash, cash equivalents, and marketable securities that we project will fund us into q2 of 2018"

* Expect to submit HDE application for marketing approval of neuro-spinal scaffold by q2 2018

* Plan to initiate first study in cervical SCI in Canada in coming months Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐